Tamoxifen, Endoxifen, and CYP2D6: The Rules for Evaluating a Predictive Factor The Kuderer/Peppercorn Article Reviewed

被引：0
|
作者：
Goetz, Matthew P. [1 ,2 ]
机构：
[1] Mayo Clin, Dept Oncol, Rochester, MN 55905 USA
[2] Mayo Clin, Dept Pharmacol, Rochester, MN USA
来源：
ONCOLOGY-NEW YORK | 2009年 / 23卷 / 14期
关键词：
BREAST-CANCER; WOMEN; THERAPY; ADHERENCE; BIOTRANSFORMATION; ANASTROZOLE; METABOLISM; GENOTYPE; OUTCOMES;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1233 / 1236
页数：3
相关论文
共 50 条
  • [1] CYP2D6 Testing for Breast Cancer Patients: Is There More to the Story? The Kuderer/Peppercorn Article Reviewed
    Henry, N. Lynn
    Hayes, Daniel F.
    Rae, James M.
    ONCOLOGY-NEW YORK, 2009, 23 (14): : 1236 - 1249
  • [2] CYP2D6 and CYP3A influence tamoxifen and endoxifen
    Laffman-Johnson, Elise
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 96 (05) : 524 - 525
  • [3] CYP2D6 and Endoxifen in Tamoxifen Therapy: A Tribute to David A. Flockhart
    Skaar, Todd C.
    Desta, Zeruesenay
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 (05) : 755 - 757
  • [4] Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice
    Kathryn J. Ruddy
    Stephen D. Desantis
    Rebecca S. Gelman
    Alan H. B. Wu
    Rinaa S. Punglia
    Erica L. Mayer
    Sara M. Tolaney
    Eric P. Winer
    Ann H. Partridge
    Harold J. Burstein
    Breast Cancer Research and Treatment, 2013, 141 : 421 - 427
  • [5] Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice
    Ruddy, Kathryn J.
    Desantis, Stephen D.
    Gelman, Rebecca S.
    Wu, Alan H. B.
    Punglia, Rinaa S.
    Mayer, Erica L.
    Tolaney, Sara M.
    Winer, Eric P.
    Partridge, Ann H.
    Burstein, Harold J.
    BREAST CANCER RESEARCH AND TREATMENT, 2013, 141 (03) : 421 - 427
  • [6] Simplified phenotyping of CYP2D6 for tamoxifen treatment using the N-desmethyl-tamoxifen/ endoxifen ratio
    Lee, Clara Inkyung
    Low, Siew Kee
    Maldonado, Ricardo
    Fox, Peter
    Balakrishnar, Bavanthi
    Coulter, Sally
    de Bruijn, Peter
    Koolen, Stijn L. W.
    Gao, Bo
    Lynch, Jodi
    Zdenkowski, Nicholas
    Hui, Rina
    Liddle, Christopher
    Mathijssen, Ron H. J.
    Wilcken, Nicholas
    Wong, Mark
    Gurney, Howard
    BREAST, 2020, 54 : 229 - 234
  • [7] Correlation of endoxifen pharmacokinetics and CYP2D6 genotypes
    Tchu, S. M.
    Wang, P.
    Stone, J.
    Ziv, E.
    Lorizio, W.
    Wu, A.
    CLINICAL CHEMISTRY, 2008, 54 (06) : A167 - A167
  • [8] Tamoxifen, CYP2D6 and endoxifen in the treatment of hormone sensitive breast cancer: demystifying the connections
    Lee, Clara Inkyung
    Gurney, Howard
    CANCER FORUM, 2016, 40 (03) : 4 - 10
  • [9] Endoxifen Levels Associated to CYP2D6 Phenotype
    Antunes, M., V
    Santos, T., V
    Andreolla, H.
    Rosa, D. D.
    Linden, R.
    THERAPEUTIC DRUG MONITORING, 2013, 35 (05) : 710 - 710
  • [10] Therapeutic Drug Monitoring of endoxifen as an alternative for CYP2D6 genotyping in individualizing tamoxifen therapy
    Schultink, Aurelia H. M. de Vries
    Huitema, Alwin D. R.
    Beijnen, Jos H.
    BREAST, 2018, 42 : 38 - 40
12345